Share Issue/Capital Change • Dec 18, 2025
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information ![]()
RNS Number : 0209M
Eco Animal Health Group PLC
18 December 2025
18 December 2025

ECO Animal Health Group plc
("ECO" or the "Company")
Exercise of Share Options and Director/PDMR Shareholdings
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Christopher Wilks, Chief Financial Officer, has exercised 4,309 nominal cost share options granted under the Company's Deferred Bonus Share Options scheme (the "Scheme"). These share options were granted on 12 December 2022 as a deferral of one-third of Mr Wilks' bonus relating to the year ended 31 March 2022.
The exercise has been fully satisfied through the transfer of existing ordinary shares held by the ECO Animal Health Group Employee Benefit Trust ("EBT"). No new ordinary shares have been issued in connection with this transaction.
As a result of this transaction, Mr. Wilks' total beneficial shareholding in the Company is now 178,186 ordinary shares, representing approximately 0.26% of the Company's issued share capital ("ISC").
Therefore, the total number of ordinary shares with voting rights in the Company remains at 67,759,671. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The notifications below, provided in accordance with the requirements of the UK Market Abuse Regulation, provide further details
-Ends-
For further information please contact:
| ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer) |
020 8447 8899 |
| ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson |
020 3709 5700 |
| Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Samed Ethemi |
020 7496 3000 |
| Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden |
020 3100 2000 |
| Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards
1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
Christopher Wilks
2.
Reason for the notification
a.
Position/status
Chief Financial Officer
b.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Eco Animal Health Group Plc
b.
LEI
2138009XN9DJ3YP7OB55
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type of instrument
Identification code
Options over ordinary shares of 5p each.
GB0032036807
b.
Nature of the transaction
1. Nominal cost share awards under the Company's Deferred Bonus Share Options ("DBS").
c.
Price(s) and volume(s)
| Price(s) | Volume(s) | ||
| 2. | DBS | 5p | 4,309 |
d.
Aggregated information
Aggregated volume
Price
n/a
e.
Date of the transaction
17 December 2025
f.
Place of the transaction
Off Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCGZMMZLNKGKZM
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.